Abivax S.A. Annual Report - How They Did This Year

Hey there! Thinking about Abivax S.A. as an investment? Let's break down their past year in plain English. You can get a good feel for what's going on. Think of this as a chat with a friend trying to make sense of financial jargon. This report covers their financial activities and assets, especially looking at 2023 and plans for 2024 and 2025. This latest report covers their performance and status for the fiscal year ending December 31, 2025.

Quick Company Facts & Status

Let's start with some basic info about Abivax. When we say "Abivax" or "the company," we mean Abivax SA and its main subsidiary. They are a company based in France. Their main offices are in Paris. Marc de Garidel leads the company as CEO. The company officially started on December 4, 2013.

If you want to invest, find their shares trading on The Nasdaq Global Market. The ticker symbol is ABVX. Each American Depositary Share (ADS) you buy represents one of their ordinary shares.

The company also has important labels that tell us about its standing:

• Well-known seasoned issuer: This means they are an established company. They have a significant market value. They also have a good track record of filing reports with the SEC. Regulators see them as transparent and stable.
• Accelerated filer: They are a company with a high value of publicly traded shares. This means they must file annual reports faster than smaller companies. It is another sign of their size and compliance.
• Emerging growth company: This label means they are still relatively new. Their annual revenue is under $1.235 billion. This status gives them flexibility in reporting. It helps them focus resources on growth. It is interesting they are both "well-known seasoned" and "emerging growth." This shows they are growing quickly. They have also achieved market recognition.
• Accounting Standards: They use International Financial Reporting Standards (IFRS) for financial statements. These are global accounting rules, not U.S. accounting rules (U.S. GAAP). This is standard for many international companies listed in the U.S. Their financial numbers are presented in euros (€).

Funding Their Mission: A Look at Their Financial Moves

Biotech companies often need much money for research and development. Abivax is no different. In 2023, they actively secured funds. They raised money through "Registered Direct Offerings" in February and October. This means they sold shares directly to investors. They also completed significant "Cross-Over Financings" in February and August. These are typically large funding rounds from institutional investors. To further support their work, they took on "Convertible Bond Loans" and "Convertible Notes." These are essentially loans from partners like Kreos and Heights. These loans can convert into company shares later. This shows they successfully attracted various types of capital. They use this to push projects forward. As a result, they had 78,536,412 total shares available as of December 31, 2025. They also plan similar financing activities. These include "Free Shares" and "Share Subscription Warrants." These plans extend into 2024, 2025, and even 2026. This shows they plan to keep raising money.

It is important to know that Abivax is a clinical-stage company. They do not have any approved products yet. Therefore, they have no revenue from selling products. They have also had considerable losses historically. They expect these losses to continue, and possibly increase, in the future. Most past operating income came from research collaborations. These were not related to their main drug candidate, obefazimod. They actually do not expect to generate any revenue from product sales for the next several years, if ever. This means they will continue to rely heavily on funding rounds to keep operations going.

Looking at their recent performance, their money lost has significantly increased:

• In 2023, they lost €147.7 million.
• In 2024, this loss grew to €176.2 million. This is an increase of approximately 19.3% from the previous year.
• In 2025, their loss jumped even further to €336.1 million. This is an increase of about 90.75% from 2024.

As of December 31, 2025, they have accumulated €912.9 million in past losses. This shows a clear trend of increasing costs. They push their research and development forward. They expect these expenses to keep growing. This is as they move drug candidates through clinical trials. They also seek regulatory approvals. They build manufacturing capabilities. And they set up sales and marketing teams. Also, if their main drug, obefazimod, gets sold, they will pay royalties. This will reduce the cash they get from sales, especially early on.

What They Own: Their Assets and Research Focus

When we look at what Abivax owns, it is a mix of things you can touch and things you cannot. These are crucial for a biotech firm.

• Intangible Assets (Their Brainpower & Intellectual Property): These are things you cannot physically touch. But they are incredibly valuable. Examples include their licenses, computer software, and patents. They have specific projects mentioned. These include 'Wittycel SAS ABX196' (a past HIV therapeutic vaccine project). Also, 'Splicos SAS ABX464' is their lead drug candidate, obefazimod. These assets have been consistently present and evolving from 2022 through 2025. They also have important licensing agreements. These are with well-known institutions. Examples include The Scripps Research Institute, the University of Chicago, and Institut Curie. This highlights their strong scientific collaborations.

  • They also have €18.4 million in "goodwill" listed in their financial records. This is the value of a past acquisition (related to obefazimod). It is more than just the physical assets they bought. It represents things like brand reputation, customer lists, or proprietary technology. They have not had to reduce this value. This means they found no reasons for it to be worth less in 2023, 2024, or 2025. But there is always a risk they might have to in the future if things do not go as planned.

• Property, Plant & Equipment (Their Workspace): Like any company, they have physical assets. These include buildings, office equipment, and computer systems. These are essential for their labs and administrative operations. These physical assets have also been part of their financial records from 2022 through 2025.

What Are the Big Hurdles? (Key Risks for Investors)

Investing in a biotech company like Abivax comes with specific risks. You should be aware of these. Here are the main ones:

• No Approved Products or Sales Yet: They are a "clinical-stage" company. They have no drugs approved for sale. They have made no money from selling products. This makes predicting their future financial success very hard.
• Ongoing and Increasing Losses: They have lost much money in the past. These losses are growing significantly year-over-year. In 2023, they lost €147.7 million. This loss grew to €176.2 million in 2024, a 19.3% increase. In 2025, their loss jumped to €336.1 million, up 90.75% from 2024. They expect to keep losing money, possibly even more. This is due to their expensive research and development. They have accumulated €912.9 million in past losses. This shows they have not made a profit. They do not expect to become profitable. This depends on their main drug, obefazimod, getting approved and sold successfully.
• Drug Development is Risky and Costly: Developing a drug is risky and costly. It takes a very long time. There is no guarantee it will work or get approved. Clinical trials can fail at any stage. Good early results do not guarantee later trial success. Many companies, even big ones, see promising drugs fail in late-stage (Phase 3) trials. Abivax could face similar setbacks. Trial results can vary. This is due to changes in how trials run, patient groups, dosing, or patient dropouts. Obefazimod has shown positive results so far. Still, future trials are not guaranteed to succeed.
  • Trials can fail for many reasons. These include poor design or wrong dose selection. The 'placebo effect' can also be a factor. Finding the right patients can be difficult. Regulators might also interpret data differently. This could delay or prevent approval.
  • Running the Trials is Tough: Running trials is tough. It involves more than just science. Abivax faces many practical challenges. They might have delays agreeing with trial sites or investigators. Companies that help run studies (CROs) also need agreements. These talks can be long and complex. Trials might need more patients than expected. Patients might also drop out too often. If CROs fail to follow rules, it causes major disruptions. Abivax might need to find new sites or investigators. All these issues can increase costs. Delays mean fixed costs keep adding up. Regulators or safety boards might suspend trials. This happens if participants face health risks or rules are broken. Abivax also needs a steady, high-quality supply of drug candidates. This can be a challenge.
  • Unexpected Side Effects: Drugs can have unexpected side effects. This can happen during trials or after approval. Such effects could stop trials or delay approval. They might also lead to strong safety warnings. Or, the drug could be pulled from the market. Severe side effects might limit the drug's use. They could even force Abivax to abandon its development.
  • Patient Recruitment Challenges: Finding enough specific patients for trials is a major hurdle. This greatly affects trial timing. Slow recruitment or high patient dropouts delay trials. This also burns through cash faster. Many factors make this difficult. These include the target patient group's size. The disease's severity matters. Other approved treatments might be preferred. Strict eligibility rules limit participants. Doctors and patients weigh risks and benefits. Competition from other companies is a factor. Practical issues like trial site location also matter. Instability in trial regions can also cause problems. Abivax relies on outside partners for this. They do not fully control how these partners perform. Without enough patients, they might abandon a trial.
  • Animal Testing Controversies: Laws often require animal testing for drug candidates. This happens before human trials. However, animal rights groups often protest these activities. They push for new laws or disrupt tests. If these groups succeed, it could interrupt or delay Abivax's research and development.
  • Regulatory Roadblocks: Health authorities create regulatory roadblocks. Agencies like the EMA in Europe or FDA in the US must approve every trial step. They also approve the drug itself. They can give negative opinions or refuse permission. They might demand more studies. This could stop or greatly delay drug development.
    • Regulators, especially the FDA, might demand more data. This could include long-term toxicology studies. They might impose other requirements before trials start. This is especially true if initial data came from outside the U.S. Regulators can also inspect trial sites or factories. Unfavorable inspections cause huge delays. They can even prevent product approval.
    • Even with approval, regulators might add strict conditions. This could limit advertising. They might require only specialists to prescribe it. Use could be restricted by age. Strong warnings might be added. They could demand a 'Risk Evaluation and Mitigation Strategy' (REMS). This means extra steps like patient guides or restricted distribution. All this makes wide sales harder. Regulators might also interpret data differently. This leads to more delays or rejections.
    • Abivax must meet 'Good Manufacturing Practice' (GMP) standards. These are strict rules for making drugs. Regulators like the FDA can inspect facilities anytime. Failing inspections or not getting GMP certificates causes huge delays. It can stop trials or prevent approval. Not following rules can bring serious penalties. These include fines, forced suspensions, recalls, or even criminal charges.
    • Government Agency Disruptions: Government agencies can face disruptions. Budget cuts, funding shortages, or global health crises affect regulators. These issues can furlough staff. They slow down reviews or prevent inspections. This could greatly delay or stop Abivax's products. Approval or commercialization would suffer.
    • Off-Label Promotion Risks: The FDA strictly controls drug marketing. Approvals are only for specific diseases and uses. Doctors can prescribe drugs for unapproved ('off-label') uses. But Abivax can only promote what the FDA approves. Promoting off-label uses brings huge fines. It also brings legal penalties. This would severely hurt their business and finances.
  • Uncertainty of Obefazimod's Unique Approach: Obefazimod has a unique approach. It enhances a specific microRNA (miR-124). No similar immune treatments are approved. This makes its path to development uncertain. Profitability and acceptance by doctors are also uncertain. Animal test results don't always translate to humans. Positive early human trials don't guarantee success in larger, later trials.
  • Abivax does not fully control many factors. These include clinical development and regulatory submissions. Threats to their intellectual property are also a factor. Manufacturing, marketing, distribution, and sales efforts are not fully controlled.
• Highly Dependent on One Drug (Obefazimod): Abivax relies heavily on one drug: obefazimod. Much of their future success depends on it. If obefazimod fails to get approval, it is a major setback. Their other drugs are in very early stages. Not getting or keeping approval, especially in key markets, would severely hurt the company.
  • Even after approval, new side effects could emerge. Negative interactions might also be found. Regulators could withdraw approval. They might demand more warnings or special guides. This could lead to lawsuits. Doctors and patients might avoid the drug. Sales would plummet, and their reputation would suffer.
  • Complex Global Approval Process: Global drug approval is complex. It is a long, expensive, and uncertain journey. Each country or region has strict rules. This includes the EU (EMA), US (FDA), and Japan (PMDA). Abivax must submit vast data. This covers safety, effectiveness, manufacturing, and quality. Approval in one country does not guarantee it elsewhere. Delays or rejections can occur. This is due to requests for more data. Different data interpretations or long review times also cause issues.
  • Risk of Narrow Approval: Even if obefazimod gets approved, it might only be for very specific, narrow uses. This would limit the number of patients who can use it. It would also significantly reduce its potential market size.
  • Reliance on Industrial Partners: Abivax relies on industrial partners. They might need big pharma partners. These partners would help fund and manage late-stage development. They would also handle production, distribution, and marketing. If Abivax cannot find good partners, or if partners perform poorly, obefazimod's success is at risk. This would hurt Abivax's growth and financial health. They might not secure partnerships on good terms, or at all.
• Challenges of Commercialization: Commercializing a drug has challenges. Even with approval, Abivax must build a sales team. They need to market the product and set up distribution. Insurance companies and governments must agree to cover costs. This is a huge task. A drug's market success depends on many factors:
  • Do doctors believe it truly benefits patients?
  • How do different countries' healthcare rules affect its use?
  • Do new side effects pop up after it is on the market?
  • Is it easy for patients to use (e.g., how it is given)?
  • Is the cost acceptable to patients and healthcare systems?
  • Will governments and private insurers pay for it?
  • How effective are their sales and marketing efforts?
  • Can they publish strong scientific data to support its use?
  • Are patients willing to try a new therapy? Are doctors willing to prescribe it?
  • Are there other, possibly better or cheaper, treatments already out there or coming soon?
  • Are there limitations on using it with other medications?
  • Abivax aims to meet unmet medical needs. But if they cannot get wide adoption, it hurts their profits. Future royalty payments will also reduce their cash from sales.
• Growing Pains: Abivax expects significant team growth. Managing this rapid expansion can be difficult. It could disrupt operations. This is especially challenging with limited money. Their current management also has limited experience with such growth. This lack of experience could cause inefficiencies. It might lead to strategic planning errors. Integrating new staff and processes could be hard. This could hinder future success. Growth also brings significant costs. It can distract management from daily tasks.
• Reliance on Third Parties: They depend on a few outside suppliers and manufacturers. These provide their drug candidates. If something goes wrong with these partners, it could impact their ability to develop and produce drugs.
• Keeping Key Talent: Their success relies on keeping top executives. They also need to attract new, qualified scientists and staff.
• Financial Reporting Weaknesses: Abivax has 'material weaknesses' in financial reporting. This means significant problems exist in their internal controls. These gaps could affect financial information accuracy and timeliness. This is not good for investor confidence. Specifically, they lack a strong process for assessing risks. This means they might not find or handle business, operational, or financial risks well. This weakness could cause unforeseen problems. It could lead to wasted resources. It might even cause major errors in financial reports. This hurts investor confidence. It could also expose them to regulatory checks or financial losses.